Legend Biotech Corporation
LEGN
$34.86
$1.374.09%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 56.46% | 59.12% | 70.28% | 38.54% | 115.08% |
| Total Other Revenue | -- | 98.16% | -93.59% | -99.88% | -97.30% |
| Total Revenue | 56.46% | 64.21% | 69.99% | 36.74% | 107.47% |
| Cost of Revenue | 51.04% | 26.05% | 51.30% | 20.37% | 11.24% |
| Gross Profit | 99.54% | 888.75% | 376.19% | 150.64% | 135.33% |
| SG&A Expenses | 24.28% | 21.68% | 9.75% | 23.28% | 29.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 220.00% | -- | -- | -- | -- |
| Total Operating Expenses | 43.86% | 25.04% | 36.96% | 21.20% | 16.45% |
| Operating Income | 3.68% | 72.50% | 38.24% | 47.87% | 56.14% |
| Income Before Tax | 46.47% | -148.34% | 67.68% | -594.48% | -65.92% |
| Income Tax Expenses | -33.33% | -21.20% | -86.11% | 157.52% | 35,900.00% |
| Earnings from Continuing Operations | 46.24% | -217.12% | 68.33% | -589.05% | -68.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.24% | -217.12% | 68.33% | -589.05% | -68.92% |
| EBIT | 3.68% | 72.50% | 38.24% | 47.87% | 56.14% |
| EBITDA | 4.05% | 75.18% | 40.00% | 49.78% | 56.74% |
| EPS Basic | 46.63% | -216.24% | 68.56% | -583.63% | -67.34% |
| Normalized Basic EPS | 46.86% | -145.43% | 67.90% | -588.78% | -63.07% |
| EPS Diluted | 45.42% | -225.92% | 67.83% | -580.90% | -67.34% |
| Normalized Diluted EPS | 46.86% | -149.89% | 67.90% | -588.78% | -63.07% |
| Average Basic Shares Outstanding | 0.73% | 0.77% | 0.74% | 0.84% | 0.96% |
| Average Diluted Shares Outstanding | 0.73% | -8.28% | 0.74% | 0.84% | 0.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |